Skip to content
Search

Latest Stories

NHS waiting list ‘will be revamped'

Prime minister Rishi Sunak has vowed to reduce wait times in the NHS, but he admitted last week he had not made enough progress

NHS waiting list ‘will be revamped'

ENGLAND’S health service will move about 40,000 pending child consultations for ADHD, autism and other conditions from its main waiting list, a person with direct knowledge of the change said, trimming the politically sensitive list ahead of an expected election.

Prime minister Rishi Sunak has vowed to reduce wait times in the NHS, but he admitted last week he had not made enough progress, blaming strikes by healthcare workers.


New guidance for data collected this month, which will be published in April, said those waiting to see a specialist doctor in community services in two treatment categories should be removed from the headline “referral to treatment” (RTT) list, documents seen by Reuters show.

An NHS England source said around 40,000 cases, just under 10 per cent, would move from the community pediatrics category to a community data set that now numbers about 85,000. A much lower number would be moved from the main list for community medicine.

NHS England said the change would end duplication and have no impact on patient care. The RTT list is the most visible monthly indicator of pressure on the NHS and routinely makes headlines.

The provision of free health care, strained by an ageing population, a lack of investment, staff shortages and the fall-out from the pandemic, is a major concern for voters in an election expected this year.

The Conservatives are trailing Labour in opinion polls, with the opposition party on track to end more than 13 years of Tory rule.

One outside expert said moving cases from the scrutiny of the main list, which at 7.6 million cases in December is close to record levels, to lower profile community data could result in less funding for child services already under pressure.

“The point of having these targets and publishing data is to reduce waiting times for patients and be accountable to the public,” said Rob Findlay, director of strategic solutions at healthcare data company Insource, which provides services to the NHS.

The change would cut the figure for those who had been waiting for more than 78 weeks by nearly nine per cent, he said, adding: “If some long-waiting services are excluded, then that protection and accountability will be lost.”

NHS England said the changes would help target care.

“Consolidating reporting of community service waits will also make it easier to analyse and understand the number of patients waiting for treatment,” a spokesperson said, without commenting on the figures.

The Royal College of Paediatrics and Child Health, which represents paediatricians, said it realised data needed improvements, but that the changes would not make children waiting more than a year for treatment feel better.

“Waiting times for children and young people are at record levels and rearranging the deckchairs alone will not help them,” it said, calling for investment in staffing community services to tackle what it said were some of the longest waits.

More For You

The Chase’s Paul Sinha shares Parkinson’s update after major health scare

Sinha’s message was one of resilience and realism

Getty

The Chase’s Paul Sinha shares Parkinson’s update after major health scare

Paul Sinha, known to viewers of ITV’s The Chase as “The Sinnerman,” has spoken candidly about his experience living with Parkinson’s disease. During an appearance on Loose Women on Thursday, 17 April, the comedian and quizzer reflected on his journey from diagnosis to managing the condition day to day.

Sinha, who was diagnosed with the progressive neurological disorder in 2019, revealed that his earliest symptoms were not what many would typically associate with Parkinson’s.

Keep ReadingShow less
Toblerone dark chocolate discontinued in the UK, confirms Mondelez

This reflects both the popularity of the product and the frustration of fans

iStock

Toblerone dark chocolate discontinued in the UK, confirms Mondelez

Toblerone fans in the UK will no longer be able to purchase the dark chocolate version of the iconic Swiss chocolate bar, as manufacturer Mondelez has confirmed it has discontinued the product.

The company stated that it has made the “difficult decision” to stop production of the 360g Toblerone Dark bar. While no specific reason was given, Mondelez acknowledged the disappointment it may cause among consumers. A spokesperson said: “While we understand that this may be disappointing for some consumers, we continue to invest in Toblerone.”

Keep ReadingShow less
Crispello Comeback: Cadbury’s Light Treat Hits B&M Shelves

The return to UK shelves has brought a wave of nostalgia for many

Getty

Cadbury Crispello chocolate bars return to UK shelves at B&M for 49p

Cadbury's Crispello chocolate bars have made a surprise return to UK stores, now available at B&M for just 49p. The product, a mix of light wafer and smooth chocolate, had previously been discontinued in the UK and was only available overseas in recent years.

Each individual pack of Crispello contains four chocolate-covered wafer fingers, filled with a creamy chocolate centre. The sweet treat has gained attention on social media, with shoppers expressing their excitement about its reappearance in British stores.

Keep ReadingShow less
 Sharon Osbourne

Celebrities including Sharon Osbourne and Oprah Winfrey might be exhibiting signs of this side effect

Instagram/ Sharonosbourne

‘Ozempic feet’ joins growing list of unusual side effects linked to popular weight-loss drug

Ozempic, the blockbuster weight-loss medication that has surged in popularity across the United States and among celebrities, is now being linked to a new and unexpected side effect like sagging skin on the feet, informally dubbed “Ozempic feet”.

Medical experts say the condition is caused by rapid fat loss, which not only alters the appearance of the face and buttocks, but can also lead to aesthetic changes in the feet. As the drug continues to make headlines for its weight-loss benefits, concerns about such side effects are also gaining attention.

Keep ReadingShow less